Adjunctive Cannabidiol Therapy in Schizophrenia

New research looks at the effects of CBD on positive and negative psychotic symptoms, cognitive performance, level of functioning, and the treating psychiatrist’s overall clinical impression.

Related Videos
Related Content

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: January 16-20

January 21st 2023

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

May 11th 2021

The Week in Review: January 9-13

January 14th 2023

Rare Copy Number Variants in Treatment-Resistant Psychosis

January 12th 2023

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: January 16-20

January 21st 2023

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

May 11th 2021

The Week in Review: January 9-13

January 14th 2023

Rare Copy Number Variants in Treatment-Resistant Psychosis

January 12th 2023

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: January 16-20

January 21st 2023

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

May 11th 2021

The Week in Review: January 9-13

January 14th 2023

Rare Copy Number Variants in Treatment-Resistant Psychosis

January 12th 2023
Advertise
Contact Us
Editorial
Terms and Conditions
Privacy Policy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.